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This consensus conference is timely, as the past decade has
witnessed an explosion of patients deemed suitable for resection
of colorectal metastases to the liver (CRLM). This is reflected in
an increased complexity of surgical procedures in patients with
more advanced disease. During the pioneering era of Fortner1
and Adson2 amongst others, less that 10% of patients with
CRLMs isolated to the liver were deemed operable. The intro-
duction of more effective chemotherapy, together with improved
radiological detection, has triggered a stepwise increase in eligible
patients such that up to 50% of patients with isolated CRLMs
may now undergo hepatic resection with excellent outcomes.3
The effectiveness of this strategy was demonstrated in the recent
paper by Swan et al.4 who reported over a 21-year period a 16%
improvement in 5-year survival in spite of operating on nine
times more patients.
The contribution of chemotherapy in downsizing and convert-
ing patients deemed inoperable into an operable situation is well
understood. The vital role of improved accuracy of radiology in
detecting lesions and charting the extent of disease is less widely
acknowledged. It is however the key element underpinning this
section of the guidelines on selection of patients for surgery of
their liver metastases.Why is radiology so pivotal? It is now estab-
lished that if chemotherapy is used alone, regressed tumour
nodules will most often recur after a variable time interval, even in
patients who have responded extremely well. In contrast, the inci-
dence of local recurrence from individual lesions that are removed
surgically is rare. Accurate detection and the optimal timing of
scans are therefore vital in our quest for recurrence-free survival.
A detected lesion removed is a problem solved. Failure to detect all
the lesions predisposes to treatment failure. It is therefore neces-
sary for us all to understand the aims of what has become a
multidisciplinary mode of therapy.
It is imperative that our best ability of CRLM detection
within the liver, namely cross-sectional imaging via computed
tomography (CT) or magnetic resonance imaging (MRI) with
liver-specific multiphase contrast protocols, is undertaken prior to
any therapeutic intervention;5 the problem of ‘disappearing
lesions’ serves to emphasize this point. In the majority of cases
when known lesions have disappeared the surgeon can use the
original radiological road map to dictate the pattern of resection,
sometimes supplemented by intra-operative ablation techniques
such as radiofrequency or microwave thermal ablation.
The staging of patients deemed suitable for resection must of
course include identifying any sites of extrahepatic disease (EHD).
Because the lung is one of the common sites of extrahepatic
metastases in patients with CRLM, dedicated CT of the chest
should be performed at the time of the initial CT for screening the
liver. The role for positron emission tomography (PET)-CT
remains less certain, especially in patients with limited spread to
the liver and in whom there was no evidence of nodal spread from
the primary tumour.While hard evidence is still lacking, it would
seem intuitive to employ PET-CT in selected cases with more
advanced tumour load with, for example, heavy initial nodal
involvement and borderline resectability of the liver.
Perhaps the more controversial aspect of these guidelines is the
concept that extrahepatic disease does not automatically preclude
liver resection. There is now circumstantial evidence that patients
with limited extrahepatic spread may be considered for resection
of the liver together with subsequent resection of EHD such as
pulmonary metastases or portal nodes. This concept is not new6
but has been reinforced by more recent data from Cresswell et al.7
that patients with synchronous presentation of liver and lung or
portal node metastases who underwent sequential resection had a
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25.5% and 29% 5-year survival, respectively. This more aggressive
approach is further encouraged in patients who demonstrate a
response to chemotherapy. For limited peritoneal carcinomatosis
complete cytoreductive surgery together with the option of hyper-
thermic intraperitoneal chemotherapy8,9 offers yet another thera-
peutic option to our armamentarium, albeit not in the context of
liver resection.
Liver resection for CRLM has come of age with more and more
of our patients offered hope of long-term survival as a treatment
goal. Achieving this goal is now dependant on a coordinated
multidisciplinary approach to define and tailor the treatment
pathway for each individual patient. In spite of our advances, one
is reminded of the philosophical words of Marty Adson that ‘our
technological ingenuity does not surpass the biologic behaviour of
the underlying cancer’.10 Marty, perhaps you will now allow us to
celebrate these guidelines11 as the first chink that perhaps we can,
after all, alter the inevitability of the behaviour of colorectal liver
metastases.
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Correction added on 11 December 2012, after first online publication:
Author correspondence details added along with reference 11 on page 2 of
the text and in the reference list.
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